Daratumumab Ready to Move to Front Line in Multiple Myeloma Daratumumab Ready to Move to Front Line in Multiple Myeloma

The first phase 3 trial in patients with newly diagnosed multiple myeloma found that daratumumab significantly improved progression-free survival when combined with triple therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news